Who makes Mecobalamin IV or IM injection?

Mecobalamin IV or IM injection is developed by Eisai Co., Ltd..

What development phase is Mecobalamin IV or IM injection in?

Mecobalamin IV or IM injection is FDA-approved (marketed).

Last reviewed 2026-05-14 · How we verify

Mecobalamin IV or IM injection

Eisai Co., Ltd. · FDA-approved active Small molecule Quality 2/100

Mecobalamin IV or IM injection, marketed by Eisai Co., Ltd., holds a position in the treatment landscape for its indicated conditions, though specific indications and revenue figures are not provided. A key strength of Mecobalamin is its established market presence, supported by a key composition patent that remains in effect until 2028. The primary risk to consider is the potential increase in competition following the patent expiry in 2028.

At a glance

Generic name	Mecobalamin IV or IM injection
Sponsor	Eisai Co., Ltd.
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety and Efficacy of Mecobalamin Injection in Peripheral Neuropathies Patients (Study JGAZSY091109) (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Mecobalamin IV or IM injection CI brief — competitive landscape report
Mecobalamin IV or IM injection updates RSS · CI watch RSS
Eisai Co., Ltd. portfolio CI